Almotriptan vs. ergotamine plus caffeine for acute migraine treatment. A cost-efficacy analysis;Almotriptán frente a ergotamina más cafeína en el tratamiento de las crisis agudas de migraña. Análisis de coste-eficacia

Neurologia

Volumn 24, Issue 3, 2009, Pages 147-153

  Slof, John ^a   Lainez J M ^b   Comas, A ^c   Heras, J ^c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c Laboratorios Almirall SA ^*  (Spain)

Author keywords

Cost efficacy; Ergotic; Migraine; Triptan

Indexed keywords

ALMOTRIPTAN; CAFERGOT;

ABSENTEEISM; ACUTE DISEASE; ADULT; AGED; ANALGESIA; ARTICLE; CALCULATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DRUG COST; DRUG EFFECT; FEMALE; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PERCEPTION; PRODUCTIVITY; QUALITY OF LIFE; SPAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; WORK;

CAFFEINE; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; ERGOTAMINE; HEALTH CARE COSTS; HUMANS; MIGRAINE DISORDERS; PATIENT SATISFACTION; QUALITY OF LIFE; TREATMENT OUTCOME; TRYPTAMINES;

EID: 65749111226     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ferrari MD. Migraine. Lancet 1998;351:1043-1051
2. Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch Neurol 2000;57:418-420 (Pubitemid 30140537)
3. Badia X, Magaz S, Gutiérrez L, Galván J. The burden of migraine in Spain: beyond direct costs. Pharmacoeconomics 2004;22:591-603. (Pubitemid 38943104)
4. Láinez JM, Vioque J, Hernández I, Titus F. Prevalence of migraine in Spain. An assessment of the questionnaires validity by clinical interview. En: Olesen J, editor. Headache classification and epidemiology. New York: Raven Press Ltd, 1994; p. 221-225
5. Freitag FG, Diamond S, Diamond ML, Urban GJ, Pepper BJ. The new treatments in migraine: first year clinical experience. Headache-Q 2000;11:33-36 (Pubitemid 30331831)
6. Winner P, Ricalde O, Le Force B, Saper J, Margul B. A double-blind study of subcutaneous dihydroergotamine vs subcutaneos sumatriptan in the treatment of acute migraine. Arch Neurol 1996;53:180-184 (Pubitemid 26055266)
7. Touchon J, Bertin L, Pilgrim AJ, Eshford E, Bes A. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in acute treatment of migraine. Neurology 1996;47:361-365 (Pubitemid 26324028)
8. MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998;98:25-30. (Pubitemid 28312075)
9. Láinez JM, Galván J, Heras J, Vila C. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur J Neurol 2007;14:269-275 (Pubitemid 46384856)
10. Zhang L, Hay JW. Cost-effectiveness analysis of rizatriptan and Sumatriptan versus Cafergot® in the acute treatment of migraine. CNS Drugs 2005;19:635-642 (Pubitemid 41058373)
11. Evans KW, Boan JA, Evans JL, Shuaib A. Economic evaluation of oral sumatriptan compared with caffeine/ergotamine for migraine. Pharmacoeconomics 1997;12:565-577 (Pubitemid 27471145)
12. Láinez JM. Prevalencia de la migraña en el medio laboral y su repercusión económica. Rev Esp de Med Trab 1995;(Suppl. 1):3-9.
13. Láinez JM. Impacto socieconómico del dolor de cabeza. Continua Neurológica 1999;2:7-16.
14. Gerth WC, Carides GW, Dasbach EJ, Visser WH, Santanello NC. The multinational impact of migraine symptoms on healthcare utilisation and work loss. Pharmacoeconomics 2001;19:197-206. (Pubitemid 32176472)
15. Von Korff M, Stewart WF, Simon DJ, Lipton RB. Migraine and reduced work performance: a population-based diary study. Neurology 1998;50:1741-1745 (Pubitemid 28283244)
16. Schwartz BS, Stewart WF, Lipton RB. Lost workdays and decreased work effectiveness associated with headache in the workplace. J Occup Environ Med 1997;39:320-327 (Pubitemid 27183608)
17. Park JW, Shin HE, Kim JS, Lee KS. Assessing migraine disability by diary-based measurement: relationship to the characteristics of individual headache attacks. Eur J Neurol 2008;15:817-821
18. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States. Arch Intern Med 1999;159:813-818
19. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646-657 (Pubitemid 32777747)
20. Instituto Nacional de Estadística. Encuesta Trimestral de Coste Laboral (ETCL) segundo trimestre de 2006.
21. García del Pozo J, Carvajal A, Grajal C, Vera E, del Pino A. Antimigraine drug consumption in Spain (1990-2000). Acta Neurol Scand 2003;107:158-160
22. IMS. Health Therapy Area Sales Report, 2006.
23. Brent RJ. Cost-benefit analysis and health care evaluations. Cheltenham: Edward Elgar Publishing Limited, 2003.
24. Sacristán JA, Badía X, Rovira J. Farmacoeconomía. Evaluación económica de los medicamentos. Madrid: Editores Médicos, 1995.
25. Chapman RH, Stone PW, Sandberg EA, Bell C, Neumann PJ. A comprehensive league table of cost-utility ratios and a sub-table of «panel- worthy» studies. Med Decis Making 2000;20:451-467
26. Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL. ¿Qué es una tecnología sanitaria eficiente en España? Gac Sanit 2002;16:334-343
27. Gracia-Naya M, Rejas J, Latorre A, González P. Evaluación económica del tratamiento de la crisis aguda de migraña con triptanes en España. Neurología 2005;20:121-132 (Pubitemid 40592977)
28. Slof J, Badia X, Magaz S, Láinez MJA, Galván J, Heras J. Cost-efficacy of oral triptans in the treatment of acute migraine. J Med Econom 2005;8:13-29. (Pubitemid 40461649)
29. Galván J, Slof J. Evaluación económica del tratamiento de la crisis aguda de migraña con triptanes en España. Neurología 2006;21:110-111
30. Slof J, Badía X, Láinez JM, Galván J, Heras J. Costes del manejo clínico de los efectos adversos torácicos y del sistema nervioso central asociados al tratamiento de las crisis agudas de migraña con triptanes orales. Neurología 2005;20:290-298